HNSCCs are genomically unstable, and this may make them especially vulnerable to therapeutics that together target NF-κB–induced antiapoptotic mechanisms and the G2/M checkpoint, which is essential in HNSCC due to loss of the G1 checkpoint by mutation or HPV-mediated degradation of TP53. This evidence concerns the gene TP53 and head and neck squamous cell carcinoma.